-
1Academic Journal
Συγγραφείς: A. V. Vorobev, V. O. Bitsadze, J. Kh. Khizroeva, S. A. Potapkina, N. A. Makatsariya, G. Rizzo, G. C. Di Renzo, D. V. Blinov, L. L. Pankratyeva, V. I. Tsibizova, А. В. Воробьев, В. О. Бицадзе, Д. Х. Хизроева, С. A. Потапкина, Н. А. Макацария, Д. Риццо, Д. К. Ди Ренцо, Д. В. Блинов, Л. Л. Панкратьева, В. И. Цибизова
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 15, No 4 (2021); 390-403 ; Акушерство, Гинекология и Репродукция; Vol 15, No 4 (2021); 390-403 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: профилактика неонатальных тромбозов, risk factors, central venous catheter, von Willebrand factor, vWF, ADAMTS-13, thrombophilia, antiphospholipid antibody circulation, thrombotic microangiopathy, neonatal thrombosis prophylaxis, факторы риска, центральный венозный катетер, фактор фон Виллебранда, тромбофилия, циркуляция антифосфолипидных антител, тромботическая микроангиопатия
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/1066/928; https://www.gynecology.su/jour/article/view/1066/929; Володин Н.Н., Ройтман Е.В., Румянцев А.Г., Шнейдер М.М. Тромбозы у новорожденных: патогенез, диагностика, лечение. Вопросы практической педиатрии. 2012;7(4):34-43.; Saracco P., Bagna R., Gentilomo C. et al.; Neonatal Working Group of the Registro Italiano Trombosi Infantili (RITI). Clinical data of neonatal systemic thrombosis. J Pediatr. 2016;171:60-6.e1. https://doi.org/10.1016/j.jpeds.2015.12.035.; Bhatt M.D., Chan A.K. Venous thrombosis in neonates. Fac Rev. 2021;10:20. https://doi.org/10.12703/r/10-20.; Raffini L., Huang Y.S., Witmer C., Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124(4):1001-8. https://doi.org/10.1542/peds.2009-0768.; Saxonhouse M.A. Thrombosis in the neonatal intensive care unit. Clin Perinatol. 2015;42(3):651-73. https://doi.org/10.1016/j.clp.2015.04.010.; Saracco P., Parodi E., Fabris C. et al. Management and investigation of neonatal thromboembolic events: genetic and acquired risk factors. Thromb Res. 2009;123(6):805-9. https://doi.org/10.1016/j.thromres.2008.12.002.; Strauss T., Levy-Shraga Y., Ravid B. et al. Clot formation of neonates tested by thromboelastography correlates with gestational age. Thromb Haemost. 2010;103(2):344-50. https://doi.org/10.1160/TH09-05-0282.; Kenet G., Nowak-Gottl U. Venous thromboembolism in neonates and children. Best Pract Res Clin Haematol. 2012;25(3):333-44. https://doi.org/10.1016/j.beha.2012.07.001.; El-Naggar W., Yoon E.W., McMillan D. et al.; Canadian Neonatal Network Investigators. Epidemiology of thrombosis in Canadian neonatal intensive care units. J Perinatol. 2020;40(7):1083-90. https://doi.org/10.1038/s41372-020-0678-1.; Kenet G., Cohen O., Bajorat T., Nowak-Gottl U. Insights into neonatal thrombosis. Thromb Res. 2019;181(Suppl 1):S33-S36. https://doi.org/10.1016/S0049-3848(19)30364-0.; Haley K.M. Neonatal venous thromboembolism. Front Pediatr. 2017;5:136. https://doi.org/10.3389/fped.2017.00136.; Veldman A., Nord M.F., Michel-Behnke I. Thrombosis in the critically ill neonate: incidence, diagnosis, and management. Vask Health Risk Manag. 2008;4(6):1337-48. https://doi.org/10.2147/vhrm.s4274.; Martin G., Thomas M.A., Wei X.C., Le D. Diffuse intracerebral hemorrhage in an infant with a novel homozygous variant leading to severe protein C deficiency. J Pediatr Hematol Oncol. 2020 Nov 6. https://doi.org/10.1097/MPH.0000000000001993.; Kraus F.T. Fetal thrombotic vasculopathy: perinatal stroke, growth restriction, and other sequelae. Surg Pathol Clin. 2013;6(1):87-100. https://doi.org/10.1016/j.path.2012.10.001.; Young G., Albisetti M., Bonduel M. et al. Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and metaanalysis of observational studies, Circulation. 2008;118(13):1373-82. https://doi.org/10.1161/CIRCULATIONAHA.108.789008.; Monagle P., Ignjatovic V., Savoia H. Hemostasis in neonates and children: pitfalls and dilemmas. Blood Rev. 2010;24(2):63-8. https://doi.org/10.1016/j.blre.2009.12.001.; Шабалов Н.П., Иванов Д.О., Шабалова Н.Н. Гемостаз в динамике первой недели жизни как отражение механизмов адаптации к внеутробной жизни новорожденного. Педиатрия. Журнал имени Г.Н. Сперанского. 2000;79(3):22.; Кольцова Е.М., Балашова Е.Н., Пантелеев М.А., Баландина А.Н. Лабораторные аспекты гемостаза новорожденных. Вопросы гематологии/ онкологии и иммунопатологии в педиатрии. 2018;17(4):100-13. https://doi.org/10.24287/1726-1708-2018-17-4-100-113.; Ignjatovic V., Pelkmans L., Kelchtermans H. et al. Differences in the mechanism of blood clot formation and nanostructure in infants and children compared with adults. Thromb Res. 2015;136(6):1303-9. https://doi.org/10.1016/j.thromres.2015.10.034.; Черкасова С.В. Гемостаз новорожденных. Практика педиатра. 2020;(1):49 -52.; Nowak-Gottl U., Limperger V., Kenet G. et al. Developmental hemostasis: a lifespan from neonates and pregnancy to the young and elderly adult in a European white population. Blood Cell Mol Dis. 2017;67:2-13. https://doi.org/10.1016/j.bcmd.2016.11.012.; Ignjatovic V. 30 years of developmental haemostasis: what have we learnt and how are we applying this knowledge. Thromb Res. 2018;172:188-9. https://doi.org/10.1016/j.thromres.2018.11.021.; Леонова Е.Ю., Синякин О.Ю. Особенности системы гемостаза у новорожденных детей. Охрана материнства и детства. 2016;(2):76-81.; Strauss T., Sidlik-Muskatel R., Kenet G. Developmental hemostasis: primary hemostasis and evaluation of platelet function in neonates. Semin Fetal Neonatal Med. 2011;16(6):301-4. https://doi.org/10.1016/j.siny.2011.07.001.; Wiedmeier S.E., Henry E., Sola-Visner M.C., Christensen R.D. Platelet reference ranges for neonates, defined using data from over 47,000 patients in a multihospital healthcare system. J Perinatol. 2009;29(2):130-6. https://doi.org/10.1038/jp.2008.14.; Strauss T., Elisha N., Ravid B. et al. Activity of Von Willebrand factor and levels of VWF-cleaving protease (ADAMTS13) in preterm and full-term neonates. Blood Cell Mol Dis. 2017;67:14-7. https://doi.org/10.1016/j.bcmd.2016.12.013.; van Ommen C.H., Sol J.J. Developmental hemostasis and management of central venous catheter thrombosis in neonates. Semin Thromb Hemost. 2016;42(7):752-9. https://doi.org/10.1055/s-0036-1592299.; Sirachainan N., Limrungsikul A., Chuansumrit A. et al. Incidences, risk factors and outcomes of neonatal thromboembolism. J Matern Fetal Neonatal Med. 2018;31(3):347-51. https://doi.org/10.1080/14767058.2017.1285892.; Marquez A., Shabanova V., Faustino E.V.S.; Northeast Pediatric Critical Care Research Consortium. Prediction of catheter-associated thrombosis in critically ill children. Pediatr Crit Care Med. 2016;17(11):e521-e528. https://doi.org/10.1097/PCC.0000000000000958.; Rupp M.E., Karnatak R. Intravascular catheter-related bloodstream infections. Infect Dis Clin North Am. 2018;32(4):765-87. https://doi.org/10.1016/j.idc.2018.06.002.; Thornburg C.D., Smith P.B., Smithwick M.L. et al. Association between thrombosis and bloodstream infection in neonates with peripherally inserted catheters. Thromb Res. 2008;122(6):782-5. https://doi.org/10.1016/j.thromres.2007.10.001.; Amankwah E.K., Atchison C.M., Arlikar S. et al. Risk factors for hospital-associated venous thromboembolism in the neonatal intensive care unit. Thromb Res. 2014;134(2):305-9. https://doi.org/10.1016/j.thromres.2014.05.036.; Andres O., Schulze H., Speer C.P. Platelets in neonates: central mediators in haemostasis, antimicrobial defence and inflammation. Thromb Haemost. 2015;113(1):3-12. https://doi.org/10.1160/TH14-05-0476.; Vorobev A., Makatsariya A., Bitsadze V. et al. Unusual thrombosis or pregnancy complications associated to ovarian cancers: two clinical cases. J Matern Fetal Neonatal Med. 2021;34(9):1430-4. https://doi.org/10.1080/14767058.2019.1638359.; Bhat R., Kumar R., Kwon S. et al. Risk factors for neonatal venous and arterial thromboembolism in the neonatal intensive care unit - a case control study. J Pediatr. 2018;195:28-32. https://doi.org/10.1016/j.jpeds.2017.12.015.; Kulkarni A.A., Osmond M., Bapir M. et al. The effect of labour on the coagulation system in the term neonate. Haemophilia. 2013;19(4):533-8. https://doi.org/10.1111/hae.12115.; Tuckuviene R., Christensen A.L., Helgested J. et al. Infant, obstetrical and maternal characteristics associated with thromboembolism in infancy: a nationwide population-based case-control study. Arch Dis Child Fetal Neonatal Ed. 2012;97(6):F417-22. https://doi.org/10.1136/archdischild-2011-300665.; Branchford B.R., Mourani P., Bajaj L et al. Risk factors for in-hospital venous thromboembolism in children: a case-control study employing diagnostic validation. Haematologica. 2012;97(4):509-15. https://doi.org/10.3324/haematol.2011.054775.; Motta M., Rodriguez-Perez C., Tincani A. et al. Neonates born from mothers with autoimmune disorders. Early Hum Dev. 2009;85(10 Suppl):S67-70. https://doi.org/10.1016/j.earlhumdev.2009.08.020.; van Ommen C.H., Nowak-Gottl U. Inherited thrombophilia in pediatric venous thromboembolic disease: why and who to test. Front Pediatr. 2017;5:50. https://doi.org/10.3389/fped.2017.00050.; Sharathkumar A.A., Mahajerin A., Heidt L. et al. Risk-prediction tool for identifying hospitalized children with a predisposition for development of venous thromboembolism: Peds-Clot clinical Decision Rule. J Thromb Haemost. 2012;10(7):1326-34. https://doi.org/10.1111/j.1538-7836.2012.04779.x.; Ovesen P.G., Jensen D.M., Damm P. et al. Maternal and neonatal outcomes in pregnancies complicated by gestational diabetes: a nationwide study. J Matern Fetal Neonatal Med. 2015;28(14):1720-4. https://doi.org/10.3109/14767058.2014.966677.; Makatsariya A., Bitsadze V., Khizroeva J. et al. Neonatal thrombosis. J Matern Fetal Neonatal Med. 2020 Mar 23:1-9. https://doi.org/10.1080/14767058.2020.1743668. [Online ahead of print].; Kristensen S.R., Kaehne M., Petersen N.E. Hemizygous antithrombindeficiency (Budapest III) in a newborn presenting with a thrombosis at birth. Br J Haematol. 2007;138(3):397-8. https://doi.org/10.1111/j.1365-2141.2007.06662.x.; Monagle P., Chan A.K., Goldenberg N.A. et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl 2):e737S-801S. https://doi.org/10.1378/chest.11-2308.; Limperger V., Klostermeier U.C., Kenet G. et al. Clinical and laboratory characteristics of children with venous thromboembolism and protein C-deficiency: an observational Israeli-German cohort study. Br J Haematol. 2014;167(3):385-93. https://doi.org/10.1111/bjh.13039.; Lee M.J., Kim K.M., Kim J.S. et al. Long-term survival of a child with homozygous protein C deficiency successfully treated with living donor liver transplantation. Pediatr Transplant. 2009;13(2):251-4. https://doi.org/10.1111/j.1399-3046.2008.00972.x.; Klostermeier U.C., Limperger V., Kenet G. et al. Role of protein S deficiency in children with venous thromboembolism. An observational international cohort study. Thromb Haemost. 2015;113(2):426-33. https://doi.org/10.1160/TH14-06-0533.; Жарков П.А. Влияние носительства полиморфизмов генов свертывающей системы крови и фолатного обмена на риск развития тромбозов у взрослых и детей. Вопросы практической педиатрии. 2012;7(5):26-32.; Arnaez J., Arca G., Martin-Ancel A., Garcia-Alix A. Coagulation factor V G1691A, factor II G20210A and methylenetetrahydrofolate reductase C677T gene mutations do not play a major role in symptomatic neonatal arterial ischaemic stroke. Br J Haematol. 2018;180(2):290-2. https://doi.org/10.1111/bjh.14308.; Kenet G., Lutkhoff L.K., Albisetti M. et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation. 2010;121(16):1838-47. https://doi.org/10.1161/CIRCULATIONAHA.109.913673.; Laugesaar R., Kahre T., Kolk A. et al. Factor V Leiden and prothrombin 20210G>A [corrected] mutation and paediatric ischaemic stroke: a casecontrol study and two meta-analyses. Acta Paediatr. 2010;99(8):1168-74. https://doi.org/10.1111/j.1651-2227.2010.01784.x.; Turebylu R., Salis R., Erbe R. et al. Genetic prothrombotic mutations are common in neonates but are not associated with umbilical catheter-associated thrombosis. J Perinatol. 2007;27(8):490-5. https://doi.org/10.1038/sj.jp.7211786.; Neshat-Vahid S., Pierce R., Hersey D. et al. Association of thrombophilia and catheter-associated thrombosis in children: a systematic review and meta-analysis. J Thromb Haemost. 2016;14(9):1749-58. https://doi.org/10.1111/jth.13388.; Mekinian A., Lachassinne E., Nicaise-Roland P. et al. European registry of babies born to mothers with antiphospholipid syndrome. Ann Rheum Dis. 2013;72(2):217-22. https://doi.org/10.1136/annrheumdis-2011-201167.; Berkun Y., Simchen M.J., Strauss T. et al. Antiphospholipid antibodies in neonates with stroke - a unique entity or variant of antiphospholipid syndrome? Lupus. 2014;23(10):986-93. https://doi.org/10.1177/0961203314531842.; Gordon O., Almagor Y., Fridler D. et al. De novo neonatal antiphospholipid syndrome: a case report and review of the literature. Semin Arthritis Rheum. 2014;44(2):241-5. https://doi.org/10.1016/j.semarthrit.2014.04.003.; Fujimura Y., Matsumoto M., Kokame K. et al. Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol. 2009;144(5):742-54. https://doi.org/10.1111/j.1365-2141.2008.07515.x.; Strauss T., Elisha N., Ravid B. et al. Activity of Von Willebrand factor and levels of VWF-cleaving protease (ADAMTS13) in preterm and full term neonates. Blood Cells Mol Dis. 2017;67:14-7. https://doi.org/10.1016/j.bcmd.2016.12.013.; Katneni U.K., Ibla J.C., Hunt R. et al. von Willebrand factor/ADAMTS-13 interactions at birth: implications for thrombosis in the neonatal period. J Thromb Haemost. 2019;17(3):429-40. https://doi.org/10.1111/jth.14374.; O'Brien S.H., Kulkarni R., Wallace A. et al. Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism. J Thromb Haemost. 2014;12(11):1822-5. https://doi.org/10.1111/jth.12716.; van Ommen C.H., van den Dool E.J., Peters M. Nadroparin therapy in pediatric patients with venous thromboembolic disease. J Pediatr Hematol Oncol. 2008;30(3):230-4. https://doi.org/10.1097/MPH.0b013e31816356f8.; Malowany J.I., Knoppert D.C., Chan A.K. et al. Enoxaparin use in the neonatal intensive care unit: experience over 8 years. Pharmacotherapy. 2007;27(9):1263-71. https://doi.org/10.1592/phco.27.9.1263.; Bauman M.E., Belletrutti M.J., Bajzar L.et al. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeuticlevels. Thromb Haemost. 2009;101(1):86-92.; Klaassen I.L.M., Sol J.J., Suijker M.H. et al. Are low-molecular-weight heparins safe and effective in children? A systematic review. Blood Rev. 2019;33:33-42. https://doi.org/10.1016/j.blre.2018.06.003.; Witmer C., Raffini L. Treatment of venous thromboembolism in pediatric patients. Blood. 2020;135(5):335-43. https://doi.org/10.1182/blood.2019001847.; Romantsik O., Bruschettini M., Zappettini S. et al. Heparin for the treatment of thrombosis in neonates. Cochrane Database Syst Rev. 2016;11(11):CD012185. https://doi.org/10.1002/14651858.CD012185.pub2.; Monagle P., Newall F. Management of thrombosis in children and neonates: practical use of anticoagulants in children. Hematology Am Soc Hematol Educ Program. 2018;2018(1):399-404. https://doi.org/10.1182/asheducation-2018.1.399.; https://www.gynecology.su/jour/article/view/1066
-
2Academic Journal
Συγγραφείς: A. V. Vorobev, A. D. Makatsariya, V. O. Bitsadze, A. G. Solopova, D. A. Ponomarev, А. В. Воробьев, А. Д. Макацария, В. О. Бицадзе, А. Г. Солопова, Д. А. Пономарев
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 15, No 3 (2021); 228-235 ; Акушерство, Гинекология и Репродукция; Vol 15, No 3 (2021); 228-235 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: факторы риска тромбозов, thrombotic complications, anticoagulant therapy, circulating antiphospholipid antibodies, APA, thrombosis risk factors, тромботические осложнения, антикоагулянтная терапия, циркуляция антифосфолипидных антител, АФА
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/1003/918; Khorana A.A., Francis C.W., Culakova E. et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–4. https://doi.org/10.1111/j.1538-7836.2007.02374.x.; Horsted F., West J., Grainge M.J. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001275. https://doi.org/10.1371/journal.pmed.1001275.; Kim A.S., Khorana A.A., McCrae K.R. Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res. 2020;225:33–53. https://doi.org/10.1016/j.trsl.2020.06.012.; Blom J.W., Doggen C.J.M., Osanto S., Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–22. https://doi.org/10.1001/jama.293.6.715.; Khorana A.A., Dalal M., Lin J., Connolly G.C. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119(3):648–55. https://doi.org/10.1002/cncr.27772.; Noble S., Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010;102 Suppl 1(Suppl 1):S2–9. https://doi.org/10.1038/sj.bjc.6605599.; Khorana A.A., Kuderer N.M., Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2015;111(10):4902–8. https://doi.org/10.1182/blood-2007-10-116327.; Ay C., Dunkler D., Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377–82. https://doi.org/10.1182/blood-2010-02-270116.; Pabinger I., van Es N., Heinze G. et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation studyin two independent prospective cohorts. Lancet Haematol. 2018;5(7):e289–e298. https://doi.org/10.1016/S2352-3026(18)30063-2.; Martín A.J.M, Ortega I., Font C. et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer. 2018;118(8):1056–61. https://doi.org/10.1038/s41416-018-0027-8.; Murthy S.B., Cushman M., Bobrow D. et al. Ability of the Khorana score to predict recurrent thromboembolism in cancer patients with ischemic stroke. J Clin Neurosci. 2018;57:111–5. https://doi.org/10.1016/j.jocn.2018.08.018.; Pabinger I., Ay C., Dunkler D. et al. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients – results from the Vienna Cancer And Thrombosis Study (CATS). J Thromb Haemost. 2015;13(1):17–22. https://doi.org/10.1111/jth.12778.; Soria J.M., Morange P.-E., Vila J. et al. Multilocus genetic risk scores for venous thromboembolism risk assessment. J Am Heart Assoc. 2014;3(5):e001060. https://doi.org/10.1161/JAHA.114.001060.; Gran O.V., Smith E.N., Brækkan S.K. et al. Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism. Haematologica. 2016;101(9):1046–53. https://doi.org/10.3324/haematol.2016.147405.; Kennedy M., Andreescu A.C.M., Greenblatt М. S. et al. Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients. Br J Haematol. 2005;128(3):386–8. https://doi.org/10.1111/j.1365-2141.2004.05327.x.; Heraudeau A., Delluc A., Le Henaff M. et al. Risk of venous thromboembolism in association with factor V leiden in cancer patients – The EDITH case-control study. PLoS One. 2018;13(5):e0194973. https://doi.org/10.1371/journal.pone.0194973.; https://www.gynecology.su/jour/article/view/1003